[Expert Panel Consensus Statement on Prevention and Standardized Treatment of Drug-induced Liver Injury in Patients with Blood Diseases (2016)]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2016 Jul 20

PMID 27431065

Affiliations

Soon will be listed here.

References

Li L, Jiang W, Wang J . Clinical analysis of 275 cases of acute drug-induced liver disease. Front Med China. 2014; 1(1):58-61. DOI: 10.1007/s11684-007-0012-8. View

Hayashi P, Fontana R . Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014; 34(2):134-44. DOI: 10.1055/s-0034-1375955. View

Danan G, Benichou C . Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46(11):1323-30. DOI: 10.1016/0895-4356(93)90101-6. View

Shen Z, Chen G, Ni J, Li X, Xiong S, Qiu Q . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9):3354-60. View

Fontana R, Watkins P, Bonkovsky H, Chalasani N, Davern T, Serrano J . Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32(1):55-68. PMC: 3637941. DOI: 10.2165/00002018-200932010-00005. View

Andrade R, Lucena M, Fernandez M, Pelaez G, Pachkoria K, Garcia-Ruiz E . Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129(2):512-21. DOI: 10.1016/j.gastro.2005.05.006. View

Green R, Flamm S . AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002; 123(4):1367-84. DOI: 10.1053/gast.2002.36061. View

Chalasani N, Hayashi P, Bonkovsky H, Navarro V, Lee W, Fontana R . ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109(7):950-66. DOI: 10.1038/ajg.2014.131. View

Fontana R, Seeff L, Andrade R, Bjornsson E, Day C, Serrano J . Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010; 52(2):730-42. PMC: 3616501. DOI: 10.1002/hep.23696. View

10.

Navarro V, Senior J . Drug-related hepatotoxicity. N Engl J Med. 2006; 354(7):731-9. DOI: 10.1056/NEJMra052270. View

11.

Singer J, Shou Y, Giles F, Kantarjian H, Hsu Y, Robeva A . UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 2007; 21(11):2311-5. DOI: 10.1038/sj.leu.2404827. View

12.

Zhang L, Wong L, He Y, Wong I . Pharmacovigilance in China: current situation, successes and challenges. Drug Saf. 2014; 37(10):765-70. DOI: 10.1007/s40264-014-0222-3. View

13.

Vuppalanchi R, Liangpunsakul S, Chalasani N . Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol. 2006; 102(3):558-62. DOI: 10.1111/j.1572-0241.2006.01019.x. View

14.

Makar G, Weiner M, Kimmel S, Bennett D, Burke A, Yang Y . Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2007; 17(1):43-51. DOI: 10.1002/pds.1514. View

15.

Suzuki A, Brunt E, Kleiner D, Miquel R, Smyrk T, Andrade R . The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011; 54(3):931-9. PMC: 3192933. DOI: 10.1002/hep.24481. View

16.

Palmore T, Shah N, Loomba R, Borg B, Lopatin U, Feld J . Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol. 2009; 7(10):1130-7. PMC: 2779698. DOI: 10.1016/j.cgh.2009.06.027. View

17.

Hochhaus A, Kantarjian H, Baccarani M, Lipton J, Apperley J, Druker B . Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2006; 109(6):2303-9. DOI: 10.1182/blood-2006-09-047266. View

18.

Zhong Y, Chen S, Li X, Hu Y, Zhang J . [Bortezomib combined with other drugs for treating 60 cases of multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009; 17(1):214-7. View

19.

Bjornsson E, Talwalkar J, Treeprasertsuk S, Kamath P, Takahashi N, Sanderson S . Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010; 51(6):2040-8. DOI: 10.1002/hep.23588. View

20.

Hayashi P . Causality assessment in drug-induced liver injury. Semin Liver Dis. 2009; 29(4):348-56. DOI: 10.1055/s-0029-1240003. View